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Abstract
Background:  N-acetyltransferase 2 (NAT2) metabolizes arylamines and hydrazines moeities
found in many therapeutic drugs, chemicals and carcinogens. The gene encoding NAT2 is
polymorphic, thus resulting in rapid or slow acetylator phenotypes. The acetylator status may,
therefore, predispose drug-induced toxicities and cancer risks, such as bladder, colon and lung
cancer. Indeed, some studies demonstrate a positive association between NAT2 rapid acetylator
phenotype and colon cancer, but results are inconsistent. The role of NAT2 acetylation status in
lung cancer is likewise unclear, in which both the rapid and slow acetylator genotypes have been
associated with disease.
Methods:  We investigated three genetic variations, c.481C>T, c.590G>A (p.R197Q) and
c.857G>A (p.G286E), of the NAT2 gene, which are known to result in a slow acetylator phenotype.
Using validated PCR-RFLP assays, we genotyped 243 healthy unrelated Caucasian control subjects,
92 colon and 67 lung cancer patients for these genetic variations. As there is a recent meta-analysis
of NAT2 studies on colon cancer (unlike in lung cancer), we have also undertaken a systematic
review of NAT2  studies on lung cancer, and we incorporated our results in a meta-analysis
consisting of 16 studies, 3,865 lung cancer patients and 6,077 control subjects.
Results:  We did not obtain statistically significant differences in NAT2  allele and genotype
frequencies in colon cancer patients and control group. Certain genotypes, however, such as
[c.590AA+c.857GA] and [c.590GA+c.857GA] were absent among the colon cancer patients.
Similarly, allele frequencies in lung cancer patients and controls did not differ significantly.
Nevertheless, there was a significant increase of genotypes [c.590GA] and [c.481CT+c.590GA],
but absence of homozygous c.590AA and [c.590AA+c.857GA] in the lung cancer group. Meta-
analysis of 16 NAT2 studies on lung cancer did not evidence an overall association of the rapid or
slow acetylator status to lung cancer. Similarly, the summary odds ratios obtained with stratified
meta-analysis based on ethnicity, and smoking status were not significant.
Conclusion: Our study failed to show an overall association of NAT2 genotypes to either colon
or lung cancer risk.
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Background
N-acetyltransferases (NAT; E.C.2.3.1.5) catalyze the
metabolism of various aromatic amine drugs and carcino-
gens. Sequence variations in the human NAT1  (MIM#
108345) and NAT2 (MIM# 243400) have been associated
with drug-induced toxicities and disease (see reviews, [1-
4]. Such sequence variations result in the production of
NAT proteins with variable enzyme activity or stability,
leading to slow or rapid acetylation. Indeed, an associa-
tion with either slow or rapid acetylation has been
reported for different cancers, systemic lupus erythemato-
sis, diabetes, and Alzheimer's disease [3]. Specifically, the
type of acetylator status may predispose a person to a par-
ticular cancer risk [5]. For instance, for cancers in which N-
acetylation is a detoxification step such as aromatic
amine-related urinary bladder, NAT2 slow acetylator phe-
notype seems at higher risk. For cancers in which N-
acetylation is negligible and O-acetylation is an activation
step such as heterocyclic amine-related colon cancer,
NAT2 rapid acetylator phenotype is at higher risk. Several
studies showed an association between slow acetylator
phenotype and urinary bladder cancer risk, as well as
rapid acetylator phenotype and colon cancer risk
(reviewed in [6]). A meta-analysis of 20 case-control stud-
ies showed, however, that NAT2 rapid acetylation status
has no specific effect on the risk of colon cancer [7]. These
conflicting results may be clarified by a careful determina-
tion of NAT2 genotypes in colon cancer patients.
So far, the role of NAT2 acetylation status in lung cancer is
unclear, in which both the rapid and slow acetylator gen-
otypes have been implicated in disease. Presumably,
exposure of lungs to various environmental carcinogens
and cigarette smoke, as well as ethnic and genetic differ-
ences, may influence results. We found at least 15 case-
control studies (five of which are published in 2005) on
NAT2  variants and lung cancer risk in different ethnic
groups and exposure variables, such as cigarette smoke
and asbestos [8-22]. Most studies obtained no overall
association of NAT2 acetylator genotypes to the develop-
ment of lung cancer, but specific risks were detected. For
instance, there was an increased risk with homozygous
NAT2*4 genotype, especially if gender, age and smoking
factors are considered [9]; with homozygous
c.341C+481T+803G and c.590A alleles [8]; with slow
acetylator genotype in adenocarcinoma in patients < 65
years old [10]; or with slow acetylator in non-operable
lung cancer, younger age, and lower smoking dose [14].
Furthermore, a significant interaction between NAT2 gen-
otype and pack-years of smoking was found, in which
rapid acetylator was protective in non-smokers, but a risk
factor in heavy smoker [17].
The human NAT2 gene is located on chromosome 8p22
[23,24] and encodes a 290-amino-acid protein. The gene
is polymorphic and 36 alleles have been so far described
[25]. Many of the NAT2*  alleles share sequence varia-
tions, and not all sequence variations would lead to
change in the enzyme activity of the coded protein. To
determine NAT2 genotypes in our colon and lung cancer
patients and control population of healthy individuals,
we investigated three sequence variations reported to
result in impaired acetylation. We did not only analyzed
overall rapid or slow acetylator genotypes, but paid partic-
ular attention to individual NAT2 genotypes which may
confer susceptibility to colon and lung cancer. We have
also undertaken a systematic review of NAT2 studies on
lung cancer and we incorporated our present results in a
meta-analysis consisting of 16 studies, 3,865 patients and
6,077 control subjects.
Methods
Informed consent blood samples were kindly provided by
Dr. C.A.D Smith of the Imperial Cancer Research Fund
Laboratory of the Ninewell's Hospital in Dundee, U.K. In
addition, JB has obtained approval to conduct genetic
studies involving human materials from the Medical
School of Hannover, Germany. All blood samples were
obtained from randomly selected, unrelated Caucasian
individuals. Using standard PCR-RFLP assay protocols, we
employed the restriction enzymes KpnI, TaqI and BamHI
to distinguish NAT2 variations c.481C>T (p.161L, dbSNP
rs1799929), c.590G>A (p.R197Q, dbSNP rs1799930)
and c.857G>A (p.G286E, dbSNP rs1799931), respec-
tively.
On the basis of these NAT2 variations, we genotyped 243
healthy unrelated Caucasian control subjects and 92
colon and 67 lung cancer patients. The reference allele
(NAT2*4) contains all three restriction sites, thus the
identification of homo- and heterozygous carriers could
easily be ascertained. In accordance with the human
NAT2 nomenclature [25], allele NAT2*4 refers to NAT2
reference sequence (Genbank accession X14672). The
NAT2*4 allele acts dominantly to result in rapid acetyla-
tion, and the presence of c.481C>T, c.590G>A, c.857G>A
would lead to slow acetylation [26]. The acetylation status
for the synonymous variation c.481C>T is not clear as this
is also associated with allele NAT2*12C  (c.481C>T +
c.803A>G) which is actually a rapid allele [1]. For the
determination of acetylator status, we classified those pos-
sessing at least two mutant alleles as slow acetylators.
Except for c.590G>A in lung cancer, genetic variations
were in Hardy-Weinberg equilibrium in colon and lung
cancer patients, as well as in controls.
Differences in allele and genotype frequency distributions
in cases and controls were determined by χ2-tests, with
significance at p ≤ 0.05. For the computation of percent-
ages, odds ratios (OR) with 95% confidence interval andBMC Medical Genetics 2006, 7:58 http://www.biomedcentral.com/1471-2350/7/58
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χ2 tests, we used the statistical package SPSS 14.0. The gen-
otype NAT2*4/*4 [c. 481CC + c.590 GG + c.857 GG] was
used as reference and ORs were calculated with respect to
this reference genotype. For the systematic review and
meta-analysis, we performed a search on Medline
(PubMed) and Embase using the keywords 'NAT2' and
'lung cancer'. We also searched references of retrieved
studies as well as reviews on NAT2. Only studies pub-
lished in English were retrieved and included in the meta-
analysis.
Meta-analysis was performed using the package rmeta of
the R-Project [27]. The Mantel-Haenszel procedure (fixed
effects model) and the DerSimonian-Laird procedure
(random effects model) were applied to analyze the odds
ratios of the studies, the summary OR, and Woolf's test for
heterogeneity. Also the 95% confidence intervals were cal-
culated for the individual and the summary odds ratios.
Results
Colon cancer
We observed the reference allele NAT2*4
[c.481C+c.590G+c.857G] in 22.3% and 28.0% for control
and colon cancer patients, respectively. Similarly, the fre-
quency of the c.481C>T variant was 48.9% and 37.5%;
the c.590G>A was 27% and 34.2%; and the c.857G>A was
1.7% and 1.6% in the control and colon cancer popula-
tions, respectively. The difference in these allele frequen-
cies as well as those of individual genotype frequencies
(Table 1) did not reach statistical significance. Neverthe-
less, the genotypes [c.590AA+c.857GA] as well as
[c.590GA+c.857GA] were not detected among the colon
cancer patients, as compared with controls. The distribu-
tion of overall genotypes was 43.5% (40/92) rapid and
56.5% (52/92) slow acetylator in the colon cancer
patients, and 37.4% (91/243) rapid and 62.6% (152/243)
slow acetylator in the controls, and the odds ratio (OR)
obtained for rapid acetylator status in cases vs. controls
was 1.29 (95% CI 0.79–2.10, p > 0.05), which was not sig-
nificant.
For the calculation of ORs for individual genotypes,
NAT2*4/*4 [c. 481CC + c.590 GG + c.857 GG] was used
as reference and all corresponding odds ratios were deter-
mined with respect to this reference (Table 1). By doing
so, the ORs measure the chance for increased risk of colon
cancer as compared to the reference, if a certain genotype
is present. This analysis did not find statistically signifi-
cant ORs, except for the genotype c.481 TT at p = 0.03 (see
Table 1).
Lung cancer
We obtained for the reference allele NAT2*4 [c.481C +
c.590G + c.857G] in 22.3% and 24.6% for control and
lung cancer patients, respectively. Similarly, the frequency
of the c.481C>T variant was 48.9% and 41.3%; the
c.590G>A was 27.0% and 31.5%; and the c.857G>A was
1.7% and 2.9% in the control and lung cancer popula-
tions, respectively. The difference in allele frequencies
between lung cancer patients and controls was not statis-
tically significant. However, carriers of genotypes
[c.590AA], [c.590AA+c.857GA] and [c.857GA], were not
Table 1: NAT2 genotypes in controls and colon cancer patients
Genotypes Deduced 
phenotypes
Controls Colon cancer Total Odds ratios 
(95% 
confidence 
interval)2
c.481 C>T c.590 G>A c.857 G>A n = 243 n = 92 n = 335
CC GG GG rapid 5.4% (13) 9.8% (9) 6.6% (22) reference
CT rapid 23.0% (56) 18.5% (17) 21.8% (73) 0.44 (0.16–1.20)
GA rapid 8.6% (21) 13.0% (12) 9.9% (33) 0.83 (0.27–2.49)
GA rapid 0.4% (1) 2.2% (2) 0.9% (3) 2.89 (0.23–
36.87)
TT slow1 22.2% (54) 13.0% (12) 19.7% (66) 0.32 (0.11–
0.92)**
AA slow 9.5% (23) 13.0% (12) 10.4% (35) 0.75 (0.25–2.26)
AA slow 0 0 0
AA GA slow 4.1% (10) 0 3.0% (10)
CT GA slow 23.9% (58) 29.3% (27) 25.4% (85) 0.67 (0.26–1.77)
CT GA slow 2.5% (6) 1.0% (1) 2.1% (7) 0.24 (0.03–2.36)
GA GA slow 0.4% (1) 0 0.3% (1)
1 c.481C>T is a silent mutation associated also with NAT*12C (c.481C>T, c.803A>G) which is a rapid allele (see Hein et al. 2000, [1])
2 For the calculation of ORs for individual genotypes, NAT2*4/*4 [c. 481CC + c.590 GG + c.857 GG] was used as reference and all corresponding 
odds ratios were determined with respect to this reference.
** significant.BMC Medical Genetics 2006, 7:58 http://www.biomedcentral.com/1471-2350/7/58
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detected within the lung cancer group (Table 2). This may
or may not be the result of the small population size, n =
67 patients. However, within the control group, the total
frequencies of these genotypes accounted for 14% or 34
individuals from 243. Furthermore, we did not detect
homozygous c.857AA (also in colon cancer patients and
controls), which is rare among Caucasians [28].
The distribution of overall genotypes was 41.8% (28/67)
rapid and 58.2% (39/67) slow acetylator in the lung can-
cer patients, and 37.4% (91/243) rapid and 62.6% (152/
243) slow acetylator in the control group, and the odds
ratio (OR) we obtained for slow acetylator status in cases
vs. controls was 0.83 (95% CI, 0.48–1.45, p > 0.05),
which was not significant. The genotype NAT2*4/*4 [c.
481CC + c.590 GG + c.857 GG] was also used as reference
for the calculation of individual ORs. In the same manner,
the ORs measure the chance for increased risk of lung can-
cer as compared to the reference, if a certain genotype is
present. The ORs obtained for individual genotypes
(Table 2) were not significant.
Many studies have been undertaken on NAT2  variants
and lung cancer risk, of which five recently published (see
Background). In contrast to colon cancer, where a meta-
analysis on 20 studies has been undertaken [7], none is
available for lung cancer. We summarized 15 published
studies (Table 3, see additional file 1) and carried out a
meta-analysis on 16 studies (including our own) to a total
of 3,865 lung cancer patients and 6,077 control subjects.
These published case-control studies were mostly hospi-
tal-based and original studies, except Sorensen et al. [18]
which was population-based and Skuladottir et al. [20],
which was based on pooled data from three studies of
Danish and Norwegian Caucasians. Basically, studies
were carried out on Caucasians, except three on Asians (2
Chinese, 1 Japanese). Samples size of lung cancer cases
ranged from 108–150 (4 studies), 153–185 (5 studies),
205–282 (3 studies), 320–392 (2 studies) and 1,115 (1
study). Average % males in 13 studies was 65%, (range 0–
100%) in cases, while in controls, 55% (0–100%). Except
for three studies [12,13,22], on which emphasis was on
never smoking women, studies were undertaken on male
smokers; for example 7 studies with 76–100% males and
89–100% smokers in lung cancer cases
[8,9,11,14,16,19,21]. As regards histology of lung cancer
cases, adenocarcinoma ranged from 19–78% in 10 stud-
ies, and in 4 studies more than 50% [10,12,13,22]. Squa-
mous cell carcinoma ranged from 20–65% in 12 studies,
and in 7 studies, average was about 50%, range 41–65%
[8,10,11,14,16,19,21]. Next frequent types were small cell
(5–35%) in 8 studies, large cell carcinoma in 4 studies
(0.04%–18%).
Results of meta-analysis showed that except for the two
studies on Chinese populations (Seow et al. [13], Chiou
et al. [22]) none of the ORs were significant (Fig. 1). For
the meta-analysis of slow acetylators (2,149/3,865 lung
cancer patients vs. 3,276/6,077 control subjects), we
obtained a summary OR value of 1.04 (95% CI 0.96–
1.14) which was not significant (Fig. 1). This meta-analy-
sis was based on a fixed effects model (Mantel-Haenszel)
which assumes that studies use identical methods,
patients and measurements, and differences are only due
to within study differences. Since the test for heterogene-
ity, however, was significant (χ2 (df 15) = 25.58, p-value
Table 2: NAT2 genotypes in controls and lung cancer patients
Genotypes Deduced 
phenotypes
Controls Lung cancer Total Odds ratios 
(95% 
confidence 
interval)2
c.481 C>T c.590 G>A c.857 G>A n = 243 n = 67 n = 310
CC GG GG rapid 5.3% (13) 7.5% (5) 5.8% (18) reference
CT rapid 23.0% (56) 13.4% (9) 21.0% (65) 0.42 (0.12–1.46)
GA rapid 8.6% (21) 20.9% (14) 11.3% (35) 1.73 (0.50–5.95)
GA rapid 0.4% (1) 0 0.3% (1)
TT slow1 22.2% (54) 13.4% (9) 20.3% (63) 0.43 (0.12–1.51)
AA slow 9.5% (23) 0 7.4% (23)
AA slow 0 0 0
AA GA slow 4.1% (10) 0 3.2% (10)
CT GA slow 23.9% (58) 38.8% (26) 27.1% (84) 1.17 (0.38–3.60)
CT GA slow 2.5% (6) 4.5% (3) 2.8% (9) 1.30 (0.23–7.31)
GA GA slow 0.4% (1) 1.4% (1) 0.6% (2) 2.60 (0.14–
50.04)
1c.481C>T is a silent mutation associated also with NAT*12C (c.481C>T+ c.803A>G) which is a rapid allele (see Hein et al. 2000, [1])
2 For the calculation of ORs for individual genotypes, NAT2*4/*4 [c. 481CC + c.590 GG + c.857 GG] was used as reference and all corresponding 
odds ratios were determined with respect to this reference.BMC Medical Genetics 2006, 7:58 http://www.biomedcentral.com/1471-2350/7/58
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0.0426), we also carried out a meta-analysis using a ran-
dom effects model (DerSimonian-Laird) which considers
both between-study and within-study variability. The
individual odds ratios for the 16 studies did not change,
but there was a small difference in the summary OR (1.05,
95% CI 0.93–1.19, and random effects variance = 0.02) as
compared to that obtained from the fixed effects model.
Nonetheless, the summary OR obtained from the random
effects model was also not significant. Furthermore, we
also performed Egger's test to assess potential publication
bias, which results from non-publication of small studies
with negative results. The Egger's test showed no evidence
of publication bias (p = 0.75).
Since the effect of NAT2 on lung cancer may be influenced
by ethnicity and smoking status, we carried out a stratified
meta-analysis of studies based on Asians, Caucasians and,
male Caucasian smokers. Although the test for heteroge-
neity was statistically significant only in the Asian studies
(p = 3e-04), results from both fixed and random effects
models were compared to determine the extent of varia-
tions. The meta-analysis on three studies on Asian popu-
lations (Oyama et al. [10], Seow et al. [13] Chiou et al.
[22]) gave a summary OR of 1 (95% CI 0.74–1.35) for
fixed effects model, while for random effects model, an
OR of 1.04 (95% CI, 0.43–2.53) and an estimated ran-
dom effects variance of 0.54. For the meta-analysis of 13
studies on Caucasian populations, the summary OR
obtained from both fixed and random effects models was
identical, e.g. 1.05 (95% CI, 0.96–1.15) (see Fig. 3). In
similar manner, the summary OR for both models was
1.03 (95% CI, 0.9–1.18) in the meta-analysis of studies
on male Caucasian smokers. Nonetheless, summary ORs
from both fixed and random effects models were not sig-
Meta-analysis (Mantel-Haenszel, fixed effects) on 16 case-control association studies on NAT2 slow acetylator status and lung  cancer Figure 1
Meta-analysis (Mantel-Haenszel, fixed effects) on 16 case-control association studies on NAT2 slow acetylator 
status and lung cancer. Test for heterogeneity χ2 (df 15) = 25.58 (p = 0.0426). The summary odds ratio (OR = 1.04, 95% CI, 
0.96–1.14) is not significant. Meta-analysis (DerSimonian-Laird, random effects) is similar, with summary OR (1.05, 95% CI 
0.93–1.19, estimated random effects variance = 0.02), likewise not significant. The confidence interval for each study is given by 
a horizontal line, and the point estimate is given by a square whose height is inversely proportional to the standard error of the 
estimate. The summary odds ratio is drawn as a diamond with horizontal limits at the confidence limits and width inversely 
proportional to its standard error.BMC Medical Genetics 2006, 7:58 http://www.biomedcentral.com/1471-2350/7/58
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nificant, and results from Egger's test did not indicate pub-
lication bias (p > 0.05).
Discussion
Genetic analysis of three NAT2  genetic variations
(c.481C>T, c.590G>A and c.857G>A) in 92 colon cancer
patients and 243 controls, both of unrelated Caucasians,
failed to show statistically significant overall association
of acetylator genotypes, in particular rapid acetylator gen-
otypes, to colon cancer risk. But certain NAT2 individual
genotype may be associated with colon cancer risk, such
as [c.481 TT], which gave statistically significant ORs,
when calculated in relation to NAT2*4/*4 as reference
genotype. This genotype showed an inverse association to
colon cancer risk and therefore may lend protection
against the disease. However, as mentioned in Methods,
the acetylation status for the synonymous variation
c.481C>T is not clear, because it is also associated with
NAT2*12C (c.481C>T+c.803A>G) which is a rapid allele
[1].
There is published evidence to suggest an overrepresenta-
tion of rapid acetylators in patients diagnosed with color-
ectal carcinoma [29] and some studies are supportive for
a relationship between intake of meat and risk of colon
cancer in certain NAT genotype constellation. Indeed, the
study of Kiss et al. [30] provided evidence for carrier of the
rapid acetylator alleles to produce higher levels of DNA
strand breaks in exfoliated colorectal mucosa cells follow-
ing a two-day "high meat" diet. Thus, the genotypes of
NAT1 and NAT2 coding for the rapid acetylator pheno-
type carry a higher risk for colorectal cancer [31]. This
association was also confirmed in a Chinese population
with diagnosed colorectal carcinoma [32]. By contrast, a
meta-analysis of 20 case-control studies on NAT2 acetyla-
tion status [7], and an investigation into an interaction
between NAT2 and heterocyclic amines derived from
meat do not provide evidence for rapid acetylators to be at
higher risk for developing colon cancer [33]. Finally, there
is interindividual variation in NAT1 and NAT2 expression
in the colon which could affect response to exposure to
specific NAT substrates including dietary carcinogens
[34].
Similar to colon cancer, the difference in allele frequencies
after genotyping the same NAT2  gene variations in 67
lung cancer patients and 243 controls was not statistically
significant. This may or may not have resulted from the
small sample size and for not taking into account, certain
exposure variables which may influence results. However,
Meta-analysis (Mantel-Haenszel, fixed effects) on 13 case-control association studies on NAT2 slow acetylator status and lung  cancer – Caucasians Figure 2
Meta-analysis (Mantel-Haenszel, fixed effects) on 13 case-control association studies on NAT2 slow acetylator 
status and lung cancer – Caucasians. Test for heterogeneity χ2 (df 12) = 9.02 (p = 0.7012). The summary odds ratio (OR 
= 1.05, 95% CI, (0.96–1.15) is not significant.BMC Medical Genetics 2006, 7:58 http://www.biomedcentral.com/1471-2350/7/58
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with the exception of two studies on Chinese populations,
none of the 15 reviewed studies found an overall associa-
tion of NAT2 acetylation genotypes to lung cancer risk
(Table 3, see additional file 1). These findings were cor-
roborated by the individual odds ratios obtained in the
meta-analysis (see Fig. 1). So far, results of all carried out
meta-analyses did not evidence overall association of
NAT2 acetylation genotypes.
Indeed, even in a very big study subjects of 1,115 lung
cancer cases, and in which age, gender, smoking status
and pack years of smoking were considered, no overall
relationship between NAT2  genotypes and lung cancer
risk was obtained [17]. Similarly, the use of 'comparison
of extremes approach' in which the distribution of NAT2
genotypes in lung cancer patients were compared not only
to the population controls, but also to elderly tumor-free
smokers and non-smokers, did not find an association
even if smoking history, gender, age or lung cancer histol-
ogy [19]. Furthermore, results of the meta-analysis also
failed to demonstrate an overall significant association of
NAT2 acetylation genotypes in lung cancer.
Closer examination, however, of the different studies on
NAT2 acetylation status and lung cancer risk, showed lack
of uniformity in the design, analysis, reporting and expo-
sure variables (e.g. smoke, asbestos) tested. These factors
may have led to discrepancy over results. Although most
studies found no overall association, specific risks were
observed. Indeed, significant associations of NAT2
acetylation genotypes to lung cancer risk were obtained
from non-smoking women Chinese women [13,22], and
not on male smokers which were mainly the case subjects
in several studies (for example, 7 studies with 76–100%
males and 89–100% smokers in lung cancer cases
[8,9,11,14,16,19,21]). Yet different results have been
observed on non-smoking Chinese women; e.g. either the
slow acetylator genotype was associated with increased
risk of lung cancer among non-smoking Chinese women
in Singapore [13], or the rapid acetylator genotype was
associated with an increase risk of lung cancer among
never smoking Chinese women in Taiwan [22].
There are also other factors which may modify susceptibil-
ity to lung cancer. For instance, NAT2 genotypes may pro-
Meta-analysis (Mantel-Haenszel, fixed effects) on 7 case-control association studies on NAT2 slow acetylator status and lung  cancer – Caucasians, male smokers Figure 3
Meta-analysis (Mantel-Haenszel, fixed effects) on 7 case-control association studies on NAT2 slow acetylator 
status and lung cancer – Caucasians, male smokers. The summary odds ratio (OR = 1.03 (95% CI, 0.9–1.18) is not sig-
nificant.BMC Medical Genetics 2006, 7:58 http://www.biomedcentral.com/1471-2350/7/58
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vide a risk to lung cancer when combined with other
genes. Individuals, with combined NAT1 rapid and NAT2
slow genotype seemed to have significantly elevated ade-
nocarcinoma risk [16], or the NAT2 slow genotype when
combined with the GSTM1  null genotype may confer
increased susceptibility to adduct formation, gene muta-
tion and lung cancer when the smoking dose is low [35].
The combination NAT2  slow-CYP1A1  rapid acetylator
were at highest risk for lung adenocarcinoma in non-
smoking females [36] or the NAT2-CYP1A1 rapid acetyla-
tors may also predispose higher risk to lung cancer in
female never smokers [22].
Conclusion
Our study failed to show an overall association of NAT2
genotypes to either colon or lung cancer risk, but results
are underpowered due to small sample size and to other
factors not considered in our analysis. As certain NAT2
genotypes may render susceptibility to cancer risk, per-
haps a collaborative effort where specific NAT2 genotypes
are investigated with uniform study design, analysis,
reporting and exposure variables in different ethnic
groups is needed.
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